The topoisomerase II inhibitor teniposide mediates the cGAS-STING axis and induces tumor immunogenicity by inducing the release of high-mobility group box 1 (HMGB1) and type I IFN signaling in tumor cells. Here, CGAS is linked to neoplasm.